TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03217227

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging with Exercise Bike
Description: A rest scan is performed and a gadolinium contrast may be administered during the scan (depending on the kidney function). After the rest scan is completed, images of the subject's heart during exercise via cycling in the supine position, will be scanned.

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging with Exercise Bike
Description: A rest scan is performed and a gadolinium contrast may be administered during the scan (depending on the kidney function). After the rest scan is completed, images of the subject's heart during exercise via cycling in the supine position, will be scanned.

Intervention type: PROCEDURE
Intervention: Cardiac Catheterization
Description: It is a procedure to diagnose and treat cardiovascular diseases by inserting a long and thin tube known as a catheter into the artery or vein in the neck, groin or arm and threaded through the blood vessels to the heart.~A coronary angiogram is also performed during the procedure where an invisible contrast dye (only visible in the X-rays) is injected through the catheter and X-ray images scanned will show the flow of the dye through the heart arteries to determine any blockages in the arteries.~In the case where there is severe narrowings, fractional flow reserve (FFR) may be performed to measure the pressure in the coronary arteries.~If there is no significant narrowing lesions, the interventionist may perform additional flow resistance measurements of the small vessels to further investigate the cause of angina

Intervention type: OTHER
Intervention: Retinal Photography (Optional)
Description: The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.

Intervention type: DIAGNOSTIC_TEST
Intervention: I123 MIBG Scintigraphy (Optional)
Description: The test studies the cardiac sympathetic signalling that may help to identify patients with high risks of adverse events. The scan consists of 2 acquisitions of images 3-4 hours apart.~For this study, only patients without clinically significant lesions (diagnosed via the cardiac catetherisation and have normal FFR results) will undergo this test.
Study: NCT00136084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone
Description: Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
Description: Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
Study: NCT03388138

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A with ketotifen
Description: Etafilcon A with ketotifen

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 1-Day ACUVUE
Description: 1-Day ACUVUE
Study: NCT00748475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Study: NCT03509675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen suspension 5mg/100ml
Description: Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study: NCT03905798

Intervention type: DRUG
Intervention: Lorazepam
Description: The usual dose of lorazepam in adults is 4 mg administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 4 mg may be added but the dose should not exceed 8 mg as the sum of initial and additional doses.~The usual dose of lorazepam in children aged 3 months or older is 0.05 mg/kg (up to 4 mg) administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 0.05 mg/kg may be added but the dose should not exceed 0.1 mg/kg as the sum of initial and additional doses.
Study: NCT01257620

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.
Study: NCT03689361

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: MRI
Description: Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI control
Description: MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 \*, vascular sequences (AngioRM and TOF) and perfusion)

Intervention type: OTHER
Group type: OTHER
Intervention: telephone consultation
Description: telephone consultation
Study: NCT01539187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VizAblate System
Description: VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy
Study: NCT03427723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein®400
Description: The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
Study: NCT02401503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Debulking: Cycles 1-2, d1 \& 2: 70mg/m² i.v.
Study: NCT03146234

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-GPC3 T cells
Description: Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.~Classical 3+3 dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study.
Study: NCT04055597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot and tDCS on-line
Description: Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Robot and sham tDCS
Description: Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
Study: NCT01064895

Intervention type: DEVICE
Intervention: Benephit catheter for Targeted Renal Therapy
Description: Local physician-specified agent delivery to the kidneys bilaterally via the renal arteries using the Benephit infusion system.
Study: NCT01885091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinerase
Study: NCT02313610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qinbudan
Description: Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qinbudan Placebo
Description: Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
Study: NCT00743912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifaximin
Description: 550 mg TID
Study: NCT03810066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: All patients will be treated with osimertinib 80 mg/d for one cycle (28 days).
Study: NCT02848001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90009
Description: CC-90009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90009
Description: CC-90009
Study: NCT00835393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole Sodium 40 mg delayed-release tablets
Description: 1 x 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROTONIX® 40 mg delayed-release tablets.
Description: 1 x 40 mg
Study: NCT03337061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Mindfulness Meditation delivered through a mobile application
Study: NCT01088477

Intervention type: OTHER
Intervention: Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol
Description: In patients with acquired antihormonal resistance, eligible for estrogen therapy, a FES-PET scan will be made to determine FES-PET tumor uptake (which corresponds to estrogen receptor expression levels). Immediately after the FES-PET scan, all patients will start with a standard accepted dose of 2mg estradiol TID. Therapy response will be monitored by regular follow-up. RECIST criteria and clinical benefit will be used as criteria. In case of disease progression before end of the study period, estradiol treatment will be stopped.
Study: NCT03438838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Heller's myotomy
Description: Laparoscopic Heller's myotomy:~Anterior wall of esophagus is exposed by opening peritoneum and minimal dissection of fat over it. Myotomy is started at 2 cm above the esophago- gastric junction. Initial plane is created using dissector and further muscles are split using pair of dissector or bowel holding forceps for length of 7 to 8 cm with 2 cm over stomach
Study: NCT03102918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo over a 6-week treatment period.
Study: NCT01762943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: All subjects will receive one IM injection (3.75 mg) each month for four months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: All subjects will receive one IM injection (3.75 mg) each month for four months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized estradiol
Description: All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized estradiol
Description: All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
Study: NCT02674620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Patients are treated with progressive exercise
Study: NCT00663208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Capsule, Oral, Approximately 182 days from initial dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Capsule, Oral, Approximately 182 days from initial dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Capsule, Oral, Approximately 182 days from initial dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Capsule, Oral, Approximately 182 days from initial dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
Study: NCT03438838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Heller's myotomy
Description: Laparoscopic Heller's myotomy:~Anterior wall of esophagus is exposed by opening peritoneum and minimal dissection of fat over it. Myotomy is started at 2 cm above the esophago- gastric junction. Initial plane is created using dissector and further muscles are split using pair of dissector or bowel holding forceps for length of 7 to 8 cm with 2 cm over stomach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Fundoplication
Description: The Fundus was sutured with 3 stitches on either side of the esophagus to right and left crus of diaphragm using ethibond(1-0) beside intervening stitch over esophagus. Width of fundoplication is kept approximately at 2cm. The proximal short gastric vessels were divided only if the fundus is insufficiently mobile
Study: NCT00663208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
Study: NCT02054507

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Cognitive evaluation (Wechsler IV tests)
Description: Children born prematurely in a level III referral Center will undergo psychometric evaluation at 8 to 11 years of age by routine test (WISC IV). The relationship between cognitive scores and neonatal characteristics will be determined and compared with the results of schoolmate control children, born at term.
Study: NCT04498793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: On Day 1 of the last seven cycles in the neoadjuvant and each cycle in the adjuvant phases of the study for a total of 21 cycles; intravenous (IV) infusion.
Study: NCT04236986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: LPS will be administered intravenously (1.0ng/kg; IV)
Study: NCT01882166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostimon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: puregon
Study: NCT05804695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic TMJ disc repositioning under GA
Description: a surgical procedure used to treat Tempro- mandibular disc displacement using arthroscope.
Study: NCT03301792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group prenatal care
Description: Enrolled subjects will be randomly assigned in a 2:1 ratio to group or traditional care.
Study: NCT04756661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: 100 mcg of Carbetocin intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 10 IU oxytocin IV drip

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 mcg rectal
Study: NCT04989543

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: vaginal swabs
Description: Nugent score: Vaginal swabbing with the dry swab, make two smears on slides.~Cytobacteriological examination: swabbing at the exo-endocrine junction using the swab~Evaluation of the vaginal microbiota: swabbing at the exo-endocrine junction using the swab

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: vaginal swabs
Description: Nugent score: Vaginal swabbing with the dry swab, make two smears on slides.~Cytobacteriological examination: swabbing at the exo-endocrine junction using the swab~Evaluation of the vaginal microbiota: swabbing at the exo-endocrine junction using the swab
Study: NCT02561429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPT
Description: SPT of histamine concentration 1, 5 and 10 mg/ml
Study: NCT03575208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B immune globulin (HBIg)
Description: HBIg 20,000 U/L iv. Dosing interval will depend on anti-HBs levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa (pegIFN)
Description: peginterferon alfa-2a 180 mcg weekly for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa (pegIFN)
Description: peginterferon alfa-2a 180 mcg weekly for 24 weeks
Study: NCT04127773

Intervention type: DEVICE
Intervention: oro gastric tube
Description: According to clinical need, an orogastric tube will be inserted at birth using the group method in VLBW infants in whom an umbilical catheter has been placed. An X-ray chest will be performed according to routine clinical practice to assess the position of the umbilical catheter. On the same X-ray the position of the gastric tube will be assessed by a radiologist blinded to the method used for orogastric tube placement.

Intervention type: DEVICE
Intervention: oro gastric tube
Description: According to clinical need, an orogastric tube will be inserted at birth using the group method in VLBW infants in whom an umbilical catheter has been placed. An X-ray chest will be performed according to routine clinical practice to assess the position of the umbilical catheter. On the same X-ray the position of the gastric tube will be assessed by a radiologist blinded to the method used for orogastric tube placement.
Study: NCT03911830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise followed cold water immersion
Description: Rehabilitation program of 17 sessions with 30 minutes of exercise followed by 15 minutes of submerged recovery at 17 ° C (3 sessions per week / 6 weeks).
Study: NCT01487525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double leg press with partial blood flow restriction
Description: double isotonic and isokinetic leg press extension with application of partial blood flow restriction to the upper leg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Double leg press without partial blood flow restriction
Description: double isotonic and isokinetic leg press extension without application of partial blood flow restriction to the upper leg
Study: NCT04233294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is a humanized anti-PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
Study: NCT01568567

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri DSM 17938
Description: One stick pack in the morning and one stick pack afternoon/evening for 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus Reuteri DSM 17938
Description: One stick pack in the morning and one stick pack afternoon/evening for 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri DSM 17938
Description: One stick pack in the morning and one stick pack afternoon/evening for 28 days.
Study: NCT00096629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human prostate-specific membrane antigen plasmid DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human prostate-specific membrane antigen plasmid DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mouse prostate-specific membrane antigen plasmid DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mouse prostate-specific membrane antigen plasmid DNA vaccine
Study: NCT04447040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/naproxen sodium Dose A
Description: Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/naproxen sodium Dose B
Description: Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/naproxen sodium Dose C
Description: Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/naproxen sodium Dose D
Description: Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/naproxen sodium Dose E
Description: Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets administered as a single two-tablet dose.
Study: NCT03684850

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based exercise
Description: Home-based exercises three times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: Home-based exercises three times per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee brace
Description: Progressive use of knee brace each day during activities of daily living.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomechanical footwear device
Description: Progressive use of footwear each day during activities of daily living.